Promising to treat patients with heart failure without diabetes, AstraZeneca is eligible for fast-track access

Heart failure is a life-threatening illness caused by the heart's inability to pump enough blood throughout the bodySymptoms of heart failure include difficulty breathing, swelling (most commonly feet, legs and feet), and fatigueIt can also lead to a significant decline in quality of life, in part because of limited physical activity and difficulties in performing typical daily activitiesThere are about 64 million patients worldwide (half of them have a lower blood-seamount, HFrEF), and nearly half die within five years of diagnosisHeart failure is one of the leading causes of hospitalization for people over 65 years of age, representing a serious clinical and economic burdenDaglenet is a "first-in-class" oral SGLT2 inhibitorSGLT2 is a transporting protein in the kidneys that assists in the reabsorption of glucoseSGLT2 inhibitors reduce glucose levels in the blood by inhibiting the function of SGLT2, allowing more glucose to drain out of the urineDuggle has received FDA approval to improve blood sugar control in people with type 2 diabetes, along with diet and exercise, and to lower their weight and blood pressureIt is also approved by the European Union for the treatment of people with type 1 diabetesIn August, the FDA granted Dagrell a net fast-track qualification to delay the progression of renal failure and prevent cardiovascular and kidney death risk soutcomes in patients with chronic kidney diseasethis fast-track eligibility is based on data analysis from two Phase 3 clinical trials, DAPA-HF and DELIVERThe efficacy of Dagrenet in treating patients with lower blood score and hFpEF retention of blood score was studied in two trials, respectivelyDAPA-HF is the first study to use SGLT2 inhibitors to treat heart failure in patients with or without type 2 diabetesIn this trial, patients with heart failure received both standard therapy and a puritanor or placeboThe results showed that heart failure patients could benefit from the net treatment of DagreDagrenet was able to reduce the risk of heart failure and cardiovascular death by 26 percent in patients with heart failure, including a 30 percent increased risk of heart failure and an 18 percent reduction in the risk of cardiovascular death In non-type 2 diabetes patients, Dageli was able to reduce the risk of heart failure by 27%, a figure comparable to that of people with type 2 diabetes the main endpoint results of subgroups of patients with heart failure without type 2 diabetes and people with heart failure of type 2 diabetes (Photo: Source: Supplied) "Heart failure affects about 64 million people worldwide, and about half of them die within five years of diagnosis," said Dr Mene Pangalos, Executive Vice President of Biomedical Research and Development at AstraZeneca We look forward to continuing to work with the FDA to explore new options for Dagrenet as a potential therapy for patients with heart failure "
References: s https:// 16, 2019, from https:// 3, Farxiga's DAPA-HF trial at ESC Retrieved September 16, 2019, from https://